Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer

ClinicalTrials.gov ID: NCT03786094

Public ClinicalTrials.gov record NCT03786094. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 5, 2026, 6:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An International, Phase 3, Multicenter, Randomized, Open- Label Trial Comparing Balixafortide in Combination With Eribulin Versus Eribulin Alone in Patients With HER2 Negative, Locally Recurrent or Metastatic Breast Cancer

Study identification

NCT ID
NCT03786094
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Spexis AG
Industry
Enrollment
432 participants

Conditions and interventions

Interventions

  • Balixafortide Drug
  • Eribulin Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 29, 2019
Primary completion
Oct 18, 2021
Completion
Oct 18, 2021
Last update posted
Oct 31, 2023

2019 – 2021

United States locations

U.S. sites
28
U.S. states
16
U.S. cities
26
Facility City State ZIP Site status
California Cancer Associates for Research and Excellence Fresno California 93720
Cedars-Sinai Medical Center Los Angeles California 90048
UCSF Mount Zion Cancer Center San Francisco California 94115
Stanford Cancer Center South Bay San Jose California 95124
Norwalk Hospital Norwalk Connecticut 06856
Florida Cancer Specialists SOUTH - SCRI - PPDS Fort Myers Florida 33901
Orlando Health Orlando Florida 32806
Florida Cancer Specialists NORTH - SCRI - PPDS St. Petersburg Florida 33705
Florida Cancer Specialists PAN - SCRI - PPDS Tallahassee Florida 32308
Tallahassee Memorial HealthCare Tallahassee Florida 32308
Florida Cancer Specialists EAST - SCRI - PPDS West Palm Beach Florida 33401
University Cancer and Blood Center, LLC Athens Georgia 30607
Piedmont Cancer Institute PC Atlanta Georgia 30318
Orchard Healthcare Research Inc Skokie Illinois 60077
Herbert-Herman Cancer Center, Sparrow Hospital Lansing Michigan 48912
Virginia Piper Cancer Institute Minneapolis Minnesota 55407
Saint Luke's Cancer Institute 150 Entrance Kansas City Missouri 63376
HCA Midwest Health - SCRI - PPDS Kansas City Missouri 64132
Mercy Research Oncology St Louis Missouri 63141
CHI Health St. Francis Grand Island Nebraska 68803
Comprehensive Cancer Centers of Nevada Las Vegas Nevada 89169
Queens Hospital Cancer Center New York New York 11432
OHSU Knight Cancer Institute Hematology Oncology Portland Oregon 97210
Magee Women's Hospital Pittsburgh Pennsylvania 15213
Sarah Cannon Research Institute Nashville Tennessee 37203
Vanderbilt University Medical Center Tennessee City Tennessee 37204
University of Vermont Medical Center Burlington Vermont 05401
West Virginia University Hospital Morgantown West Virginia 26506

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 60 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03786094, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 31, 2023 · Synced May 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03786094 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →